Surge in NASH cases, advanced clinical trials and huge pipeline of drugs likely to drive growth of NASH drugs market

The Global NASH Market, valued at USD 3.37 billion in the year 2020 has been projected to grow on the back of demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. The market is expected to be driven by rise in advanced technology such as advanced clinical trials, special MRI technology, called MR-EFF (elastography fat fraction), to determine the percentage of fat and scarring present. This non-invasive diagnostic tool may eliminate the need for a liver biopsy.

NASHs are usually associated with the rising geriatric population around the globe. However, an increasing number of younger people are opting for NASHs instead of bridges.Major factors contributing to the global NASH market growth includes focus on development of new medical strategies for NASH patients and focus on promising drugs for non-alcoholic steatohepatitis (NASH).  

Retail Pharmacy sales channel is expected to hold significant share in the market over the forecast period due to certain biopharmaceutical manufacturers or companies that sell their drugs to few retail pharmacies so they will always have an advantage with these medications. However, online services are also increasing their share because online service lets people refill any prescription currently on file with Nash Drugs.  

On the Basis of Drug Type Non-alcoholic steatohepatitis (NASH) market is segmented as vitamin E & pioglitazone, obeticholic Acid (OCA), elafibranor, and selonsertib & cenicriviroc. At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy. On the other hand, elafibranor and selonsertib & cenicriviroc segments are expected to exhibit significant growth in the future, majorly due to its effectiveness in severely affected NASH patients.

The Azoth Analytics research report ‘Global NASH Market (2021 Edition) has analysed and segmented the NASH Market by Value (USD Million). The report has further analysed the NASH Market by Sales Channel (Hospital Pharmacy, Online Provider, Retail Pharmacy), By Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, Selonsertib & Cenicriviroc, Others). The Global NASH Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA) and By Country (United States, Canada, Germany, France, United Kingdom, Italy, Japan, China, India, Mexico, Brazil) for the historical period of 2016-2020 and the forecast period of 2021-2026.